Systemic lupus erythematosus-specific factors (eg, inflammation, disease damage/duration) are associated with cognitive dysfunction, as well as chronic disease factors (eg, fatigue, depression, pain, medication).
The outcome in this case is hypothesis-generating in that it suggests that the gut microbiome may play an etiologic role in psoriatic arthritis.
A composite thrombosis risk equation including platelet C4d, low C3, and lupus anticoagulant is strongly associated with thrombosis in systemic lupus erythematosus.
Physical functioning was found to be affected by factors including the presence of comorbidities, female sex, disease duration and activity in patients with psoriatic arthritis.
Real-life data support the validity of switching from reference etanercept to SB4 for most patients with psoriatic arthritis.
In patients with gout who initiate urate-lowering therapy during an acute disease flare, C-reactive protein levels >30 mg/L and absence of prophylaxis may represent prognostic factors for early gout flare recurrence.
Treatment of bio-naive patients with ankylosing spondylitis with golimumab or infliximab for 6 months was associated with reduced healthcare resource utilization and increased work activity and activity.
Researchers evaluated the factors associated with the presence of peripheral manifestations in patients with spondyloarthritis.
Neural network technology may be useful when scoring disease activity on Doppler ultrasound images in patients with rheumatoid arthritis.
Early initiation of combination therapy with golimumab plus methotrexate doubled the number of patients achieving psoriatic arthritis remission compared with methotrexate alone.
